A biomarker study in long-lasting amnestic mild cognitive impairment

Table 1 Demographic and clinical features of the sample

	Patient sample (n = 30)
Female/male ratio	12/18
Age in years (mean ± SD)	74.1 ± 4.8
Age range in years	65–84
Years of education (mean ± SD)	10.3 ± 4.5
Disease duration in months at first evaluation (mean ± SD)	44.5 ± 25.5
Months of follow-up (mean ± SD)	58.3 ± 10.1
Disease duration in months at follow-up (mean ± SD)	102.8 ± 28.1
MMSE adjusted score at first evaluation (mean ± SD)	26.5 ± 2.1
MMSE adjusted score at follow-up (mean ± SD)	25.1 ± 2.5
CDR Sum of Boxes at first evaluation (mean ± SD)	1.91 ± 0.6
CDR Sum of Boxes at follow-up (mean ± SD)	2.9 ± 1.7
Diagnosis at first evaluation	15 s-aMCI, 15 m-aMCI
Diagnosis at follow-up	9 s-aMCI, 21 m-aMCI
Lumbar puncture (no. of subjects)	20/30
CSF Aβ₄₂ and t-tau/p-tau normal values	7/20
CSF Aβ₄₂ low values	10/20
CSF p-Tau/t-tau high values	3/20
Amyloid-PET (no. of subjects)	16/30
SUVr values from 1.0 to 1.45	8/16
SUVr values from 1.45 to 1.80	6/16
SUVr values from 1.80 to 1.90	2/16

Abbreviations: MMSE Mini Mental State Examination, CDR Clinical Dementia Rating, CSF Cerebrospinal fluid, Aβ₄₂ β-Amyloid (1–42) protein, t-tau Total tau, p-tau Phosphorylated tau, s-aMCI Single-domain amnestic mild cognitive impairment, m-aMCI Multiple-domain amnestic mild cognitive impairment, PET Positron emission tomography

ISSN: 1758-9193